NuCana says EPO grants European composition-of-matter patent for NUC-7738

• NuCana secured a European Patent Office grant for a composition-of-matter patent covering its cancer drug candidate NUC-7738.
• The company said NUC-7738 is now covered by more than 85 issued patents worldwide, including similar composition patents in the US and China.
• NUC-7738 is being evaluated in a Phase 1/2 study with Keytruda in PD-1 inhibitor-resistant metastatic melanoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300800OMX_____CNEWS_EN_GNW9836472_en) on September 30, 2026, and is solely responsible for the information contained therein.